Regeneron Pharmaceuticals Management
Management criteria checks 4/4
Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 37.33 years. total yearly compensation is $6.82M, comprised of 28.4% salary and 71.6% bonuses, including company stock and options. directly owns 2.27% of the company’s shares, worth $1.47B. The average tenure of the management team and the board of directors is 6.3 years and 18.4 years respectively.
Key information
Leonard Schleifer
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | 28.45% |
| CEO tenure | 37.3yrs |
| CEO ownership | 2.3% |
| Management average tenure | 6.3yrs |
| Board average tenure | 18.4yrs |
Recent management updates
Recent updates
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
May 21Regeneron: Still A Biotech Juggernaut
Apr 16
Dupixent And EYLEA Will Open New Therapeutic Frontiers
Promising pipeline and Dupixent’s market expansion are expected to drive revenue growth and improve net margins.Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Apr 06Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Mar 14Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Feb 04Regeneron: Phase III Success In Skin Cancer For Libtayo
Jan 15Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
Jan 05Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Dec 13
Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025
Dec 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings
Nov 22Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$7m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
| Sep 30 2019 | n/a | n/a | US$2b |
| Jun 30 2019 | n/a | n/a | US$2b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$27m | US$1m | US$2b |
Compensation vs Market: Leonard's total compensation ($USD6.82M) is below average for companies of similar size in the US market ($USD14.14M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard Schleifer (71 yo)
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 37.3yrs | US$6.82m | 2.27% $ 1.5b | |
| Co-Founder | 24.3yrs | US$6.80m | 1.09% $ 709.3m | |
| Executive VP of Finance & CFO | 1.3yrs | US$6.27m | 0.019% $ 12.1m | |
| Executive Vice President of Research | 6.3yrs | US$8.36m | 0.051% $ 32.8m | |
| Executive VP and GM of Industrial Operations & Product Supply | 17.1yrs | US$8.66m | 0.034% $ 22.1m | |
| Senior Vice President of Quality Assurance & Operations | 5.3yrs | no data | no data | |
| Senior VP of IT & Chief Information Officer | 4.3yrs | no data | no data | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | no data | no data | |
| Executive VP | 13.7yrs | US$7.13m | 0.037% $ 24.3m | |
| Senior VP & Chief Compliance Officer | 2.3yrs | no data | no data | |
| Executive Vice President of Human Resources | 9.1yrs | no data | no data | |
| Senior Vice President of Public Policy & Government Affairs | 4.3yrs | no data | no data |
Experienced Management: REGN's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 37.3yrs | US$6.82m | 2.27% $ 1.5b | |
| Co-Founder | 24.3yrs | US$6.80m | 1.09% $ 709.3m | |
| Lead Independent Director | 14.5yrs | US$769.77k | 0.00076% $ 493.7k | |
| Independent Director | 22.3yrs | US$719.77k | 0.015% $ 10.0m | |
| Independent Director | 33.9yrs | US$724.77k | 0.011% $ 6.9m | |
| Independent Director | 33.9yrs | US$709.77k | 0.0047% $ 3.1m | |
| Independent Director | 37.3yrs | US$724.77k | 0.027% $ 17.5m | |
| Independent Director | 8.3yrs | US$699.77k | 0.000010% $ 6.5k | |
| Independent Director | 2.6yrs | US$699.77k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$714.77k | 0% $ 0 | |
| Independent Director | 8.7yrs | US$709.77k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$288.99k | 0% $ 0 |
Experienced Board: REGN's board of directors are seasoned and experienced ( 18.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 10:23 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 63 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |